Clinical Study Of Banxia Houpou And Si Junzi In The Treatment Of Diarrhea Type Irritable Bowel Syndrome(liver Depression And Spleen Deficiency Type)dalian Medical University

Objective: In this study,the efficacy and safety of Banxia Houpu Decoction and Sijunzi Decoction in the treatment of diarrhoeal irritable bowel syndrome(IBS)with liver-qi stagnation and spleen-deficiency syndrome were investigated by comparing the scores of symptoms of traditional Chinese medicine,score of stool characteristics,IBS-SSS scale and Hamilton anxiety(depression)scale before and after treatment.Methods: This experiment is a randomized controlled study.The subjects involved in this experiment are patients with diarrhoeal irritable bowel syndrome(liver-qi stagnation and spleen-deficiency type)who were hospitalized in the wards and clinics of the First Affiliated Hospital of Dalian Medical University from January 2022 to January2023.A total of 83 patients met the research conditions and agreed to participate in this experiment,of which 1 case fell out for some reason.The project has passed the review of the Ethics Committee of the First Affiliated Hospital of Dalian Medical University and obtained the approval document(project number: YJ-KY-2021-263).The patients who met the requirements of traditional Chinese medicine and western medicine were randomly divided into observation group(40 cases)and control group(42 cases)according to the order of treatment by random number table.In this experiment,the observation group was treated with Banxia Houpu Decoction and Sijunzi Decoction,while the control group was treated with Trimebutine Maleate Tablets and Pividium Bromide Tablets.The course of treatment was 2 weeks.The clinical symptoms of the subjects before and after treatment were evaluated with the Chinese Medicine Syndrome Rating Scale,IBS-Severity Scale(IBS-SSS),Hamilton Anxiety Assessment Scale(HAMA)and Bristol Stool Character Scale(BSFS).The scale used in this trial can objectively reflect the degree of clinical symptoms and anxiety of subjects before and after treatment.The statistical analysis of the data in this study was carried out using SPSS 27.0 statistical software.Results:1.This study is a randomized controlled study.There were 23 males and 17 females in the observation group,with an average age of(43.80 ± 16.19)years;There were 21 males and 21 females in the control group,with an average age of(40.64 ± 15.43)years.There was no statistically significant difference in gender and age between the two groups(P>0.05).Before treatment,there was no statistically significant difference in TCM syndrome score,IBS-SSS scale score,HAMA score and BSFS score between the two groups(P>0.05).The data were comparable.2.After treatment,the total score of TCM syndrome in both groups decreased compared with that before treatment,and the total score of TCM syndrome in the observation group decreased more significantly than that in the control group(P<0.05).Compared with each single score of TCM syndromes in the two groups,the score of abdominal pain,stool frequency,stool characteristics,anxiety degree,chest fullness,abdominal distension and anorexia in the observation group decreased more significantly(P>0.05).In terms of clinical efficacy,the observation group was cured in 5cases,markedly effective in 30 cases,effective in 2 cases,and ineffective in 3 cases,with a clinical effective rate of 92.50%,while the control group was cured in 1 case,markedly effective in 7 cases,effective in 28 cases,and ineffective in 6 cases,with a clinical effective rate of 85.71%(P<0.05).3.After treatment,the score of IBS-SSS scale of patients in both groups was lower than that before treatment(P<0.05).4.After treatment,the HAMA scale scores of patients in the two groups were compared within the group,and the degree of anxiety of patients was decreased(P<0.05)5.After treatment,the BSFS score of patients in both groups decreased,and the stool properties of patients in both groups were improved compared with those before treatment.The improvement effect of the observation group was better,and the stool properties were closer to the normal BSFS4 stool.(P<0.05)Conclusion: Banxia Houpu Decoction and Sijunzi Decoction have obvious clinical effect on IBS-D(liver depression and spleen deficiency type),which can effectively alleviate the symptoms of abdominal pain and diarrhea,increase the frequency of defecation,improve the abnormal characteristics of stool,regulate the intestinal function disorder,and relieve anxiety,which is worthy of clinical promotion and application.